Illustrative image – not actual.Panacea Biotec has entered into an agreement to sell its formulation business in India and Nepal to Mankind Pharma for Rs 1,908 crore.
Panacea domestic business majorly gets its revenues from therapeutic segments such as organ transplantation, diabetes, pain, cough and cold and gastroenterology. Panacea expects to complete the transaction by the end of 2022.
Panacea domestic business majorly gets its revenues from therapeutic segments such as organ transplantation, diabetes, pain, cough and cold and gastroenterology. Panacea expects to complete the transaction by the end of 2022.
